Avelumab (MSB0010718C; anti-PD-L1) vs platinum-based doublet as first-line treatment for metastatic or recurrent PD-L1-positive non-small-cell lung cancer: The phase 3 JAVELIN Lung 100 trial.
Yazar
Chand, Vikram
Ozguroglu, Mustafa
Helwig, Christoph
Cuillerot, Jean-Marie
Westeel, Virginie
Reck, Martin
DeGreen, Hyatt P.
Rose, Andrea L.
Pavlakis, Nick
Derjcke, Sofie Maria
Radic, Jasna
Jeppesen, Nina
Thomas, Michael
Losonczy, Gyorgy
Kalinka-Warzocha, Ewa
Dreosti, Lydia Mary
Postmus, Pieter E.
Üst veri
Tüm öğe kaydını gösterBağlantı
http://hdl.handle.net/20.500.12627/45825https://doi.org/10.1200/jco.2016.34.15_suppl.tps9105
Koleksiyonlar
- Bildiri [64839]